CHGCY Quote, Financials, Valuation and Earnings

Healios KK has a net margin of 33.71% compared to Chugai Pharmaceutical's net margin of -6742.11%. Chugai Pharmaceutical's return on equity of 21.98% beat Healios KK's return on equity of -196.15%.

Chugai Pharmaceutical has a consensus price target of --, signalling downside risk potential of --. On the other hand Healios KK has an analysts' consensus of -- which suggests that it could fall by --. Given that Chugai Pharmaceutical has higher upside potential than Healios KK, analysts believe Chugai Pharmaceutical is more attractive than Healios KK.

Chugai Pharmaceutical has a beta of 0.651, which suggesting that the stock is 34.916% less volatile than S&P 500. In comparison Healios KK has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Chugai Pharmaceutical has a quarterly dividend of $0.19 per share corresponding to a yield of 1.42%. Healios KK offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Chugai Pharmaceutical pays 34.4% of its earnings as a dividend. Healios KK pays out -- of its earnings as a dividend. Chugai Pharmaceutical's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Chugai Pharmaceutical quarterly revenues are $1.9B, which are larger than Healios KK quarterly revenues of $249.2K. Chugai Pharmaceutical's net income of $637.7M is higher than Healios KK's net income of -$16.8M. Notably, Chugai Pharmaceutical's price-to-earnings ratio is 30.95x while Healios KK's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Chugai Pharmaceutical is 10.45x versus 83.05x for Healios KK. Usually stocks with elevated PS ratios are considered overvalued.

PeptiDream has a net margin of 33.71% compared to Chugai Pharmaceutical's net margin of -24.41%. Chugai Pharmaceutical's return on equity of 21.98% beat PeptiDream's return on equity of 34.1%.

Chugai Pharmaceutical has a consensus price target of --, signalling downside risk potential of --. On the other hand PeptiDream has an analysts' consensus of -- which suggests that it could fall by --. Given that Chugai Pharmaceutical has higher upside potential than PeptiDream, analysts believe Chugai Pharmaceutical is more attractive than PeptiDream.

Chugai Pharmaceutical has a beta of 0.651, which suggesting that the stock is 34.916% less volatile than S&P 500. In comparison PeptiDream has a beta of 0.523, suggesting its less volatile than the S&P 500 by 47.679%.

Chugai Pharmaceutical has a quarterly dividend of $0.19 per share corresponding to a yield of 1.42%. PeptiDream offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Chugai Pharmaceutical pays 34.4% of its earnings as a dividend. PeptiDream pays out -- of its earnings as a dividend. Chugai Pharmaceutical's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Chugai Pharmaceutical quarterly revenues are $1.9B, which are larger than PeptiDream quarterly revenues of $27.8M. Chugai Pharmaceutical's net income of $637.7M is higher than PeptiDream's net income of -$6.8M. Notably, Chugai Pharmaceutical's price-to-earnings ratio is 30.95x while PeptiDream's PE ratio is 14.08x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Chugai Pharmaceutical is 10.45x versus 4.86x for PeptiDream. Usually stocks with elevated PS ratios are considered overvalued.

Nxera Pharma has a net margin of 33.71% compared to Chugai Pharmaceutical's net margin of -11.44%. Chugai Pharmaceutical's return on equity of 21.98% beat Nxera Pharma's return on equity of -8.65%.

Chugai Pharmaceutical has a consensus price target of --, signalling downside risk potential of --. On the other hand Nxera Pharma has an analysts' consensus of -- which suggests that it could fall by --. Given that Chugai Pharmaceutical has higher upside potential than Nxera Pharma, analysts believe Chugai Pharmaceutical is more attractive than Nxera Pharma.

Chugai Pharmaceutical has a beta of 0.651, which suggesting that the stock is 34.916% less volatile than S&P 500. In comparison Nxera Pharma has a beta of 0.374, suggesting its less volatile than the S&P 500 by 62.646%.

Chugai Pharmaceutical has a quarterly dividend of $0.19 per share corresponding to a yield of 1.42%. Nxera Pharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Chugai Pharmaceutical pays 34.4% of its earnings as a dividend. Nxera Pharma pays out -- of its earnings as a dividend. Chugai Pharmaceutical's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Chugai Pharmaceutical quarterly revenues are $1.9B, which are larger than Nxera Pharma quarterly revenues of $43.6M. Chugai Pharmaceutical's net income of $637.7M is higher than Nxera Pharma's net income of -$5M. Notably, Chugai Pharmaceutical's price-to-earnings ratio is 30.95x while Nxera Pharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Chugai Pharmaceutical is 10.45x versus 2.93x for Nxera Pharma. Usually stocks with elevated PS ratios are considered overvalued.

Takeda Pharmaceutical has a net margin of 33.71% compared to Chugai Pharmaceutical's net margin of -9.79%. Chugai Pharmaceutical's return on equity of 21.98% beat Takeda Pharmaceutical's return on equity of 1.49%.

Chugai Pharmaceutical has a consensus price target of --, signalling downside risk potential of --. On the other hand Takeda Pharmaceutical has an analysts' consensus of $16.89 which suggests that it could grow by 13.81%. Given that Takeda Pharmaceutical has higher upside potential than Chugai Pharmaceutical, analysts believe Takeda Pharmaceutical is more attractive than Chugai Pharmaceutical.

Chugai Pharmaceutical has a beta of 0.651, which suggesting that the stock is 34.916% less volatile than S&P 500. In comparison Takeda Pharmaceutical has a beta of 0.223, suggesting its less volatile than the S&P 500 by 77.69%.

Chugai Pharmaceutical has a quarterly dividend of $0.19 per share corresponding to a yield of 1.42%. Takeda Pharmaceutical offers a yield of 4.42% to investors and pays a quarterly dividend of $0.34 per share. Chugai Pharmaceutical pays 34.4% of its earnings as a dividend. Takeda Pharmaceutical pays out 280.28% of its earnings as a dividend. Chugai Pharmaceutical's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Takeda Pharmaceutical's is not.

Chugai Pharmaceutical quarterly revenues are $1.9B, which are smaller than Takeda Pharmaceutical quarterly revenues of $6.9B. Chugai Pharmaceutical's net income of $637.7M is higher than Takeda Pharmaceutical's net income of -$676.5M. Notably, Chugai Pharmaceutical's price-to-earnings ratio is 30.95x while Takeda Pharmaceutical's PE ratio is 68.93x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Chugai Pharmaceutical is 10.45x versus 1.61x for Takeda Pharmaceutical. Usually stocks with elevated PS ratios are considered overvalued.